Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SGHT vs ECOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGHT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–0 Matrix Metrics)

SGHT Overall Winner 6-Pillar Tally: SGHT 3 – 2 ECOR (1 Tie) Matrix Metrics: SGHT 8 – 0 ECOR

As of Nov 20, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SGHT carries a Unified Composite Score of 53.2/100 (HOLD) at $10.18 (N/M Forward P/E, -20.2% operating margin), whereas ECOR carries 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin).

  • Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.2); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SGHT vs ECOR
SGHT NASDAQ Head-to-Head Winner
Sight Sciences, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$10.18
-4.14% 1D
Market Cap $590.2M
TTM Revenue $88M
Forward P/E N/M
Beta / 30D Vol 1.09β · 48% Vol
Unified Composite Score
53.2 / 100 HOLD
Tech 39.0 Fund 54.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.4% over 20 days), RSI 54
RSI-14: 54.2 · SMA20: $10.07 · SMA50: $9.21
ECOR NASDAQ
electroCore, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$4.42
-8.87% 1D
Market Cap $44.7M
TTM Revenue $38M
Forward P/E N/M
Beta / 30D Vol 1.55β · 155% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 30.0 Fund 60.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.1%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $6.77 · SMA50: $8.56

6-Pillar Scorecard Institutional Category Breakdown (SGHT 3 – 2 ECOR)

Columns: Metric · SGHT · ECOR
1. Valuation Multiples ECOR
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.3x 1.3x
2. Growth & Scale SGHT
Revenue Growth (YoY) +25.2% +11.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $88M $38M
Market Cap $590.2M $44.7M
3. Profitability & Quality SGHT
Gross Margin 87.7% 87.7%
Operating Margin -20.2% -33.1%
Net Profit Margin -32.1% -33.5%
Return on Equity (ROE) -50.1% -478.7%
4. Balance Sheet & Cash Flow ECOR
Cash Generation (TTM) -$17M -$6.9M
Cash Flow Margin -19.1% -18.1%
Net Cash / Leverage $35M Net Cash $4.6M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGHT
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 78.7% (8th %ile) N/A (N/A)
Put/Call OI Skew 0.01x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SGHT (8) vs ECOR (0)
Institutional Metric SGHT ECOR Criterion Row Edge
Market Capitalization
Scale
$590.2M $44.7M Larger Scale SGHT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+25.2% +11.5% Higher Growth SGHT
Operating Margin (TTM)
Profitability
-20.2% -33.1% Higher Margin SGHT
Net Profit Margin
Profitability
-32.1% -33.5% Higher Margin SGHT
Return on Equity (ROE)
Capital Efficiency
-50.1% -478.7% Higher ROE SGHT
52-Week Range Position
Momentum
83% ($3–$12) 6% ($4–$13) Stronger Trend SGHT
Beta / 30D Volatility
Risk Regime
1.09β · 48% Vol 1.55β · 155% Vol Lower Realized Risk SGHT
Unified Institutional Score
Composite Signal
53.2 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite SGHT
Trailing 12M Revenue (USD)
Operating Scale
$88M $38M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
87.7% 87.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.3x EV/Rev N/M PEG · 1.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($35M Net Cash) -$6.9M ($4.6M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGHT +52.34 pp
SGHT: +11.99% · ECOR: -40.35%
3M Horizon SGHT +75.68 pp
SGHT: +21.48% · ECOR: -54.2%
6M Horizon SGHT +136.12 pp
SGHT: +102.39% · ECOR: -33.73%
1Y Horizon SGHT +56.33 pp
SGHT: +46.9% · ECOR: -9.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SGHT Revenue ECOR Revenue SGHT Op. Margin ECOR Op. Margin Margin Leader
FY2018 N/A $0M N/A -5494.1% ECOR
FY2019 N/A $0M N/A -1928.2% ECOR
FY2020 $30M $0M -116.5% -707.9% SGHT
FY2021 $50M $10M -105.2% -367.7% SGHT
FY2022 $70M $10M -117.7% -266.2% SGHT
FY2023 $80M $20M -70.7% -120.2% SGHT
FY2024 $80M $30M -63.3% -48.3% ECOR
FY2025 $80M $30M -48.0% -41.1% ECOR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SGHT CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 8th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGHT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ECOR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SGHT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $590.2M market capitalization and -20.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ECOR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $44.7M market capitalization and -33.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SGHT vs ECOR Key Questions & Quantitative Answers

As of Nov 20, 2026, Sight Sciences, Inc. (SGHT) is the stronger overall head-to-head candidate over electroCore, Inc. (ECOR) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SGHT carries a Unified Composite Score of 53.2/100 (HOLD) at $10.18 (N/M Forward P/E, -20.2% operating margin), whereas ECOR carries 44.5/100 (HOLD) at $4.42 (N/M Forward P/E, -33.1% operating margin). Technical & Structure Timing Caution: SGHT trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.2); meanwhile ECOR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGHT leads the Growth & Scale pillar: SGHT posts +25.2% YoY revenue growth and +0.0% YoY earnings growth on $88M TTM revenue (87.7% gross margin, -20.2% operating margin), compared with ECOR at +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SGHT cumulative revenue shifted +166.7% while ECOR shifted +200.0%. In operating R&D and SG&A reinvestment, SGHT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ECOR.

ECOR screens cheaper on headline valuation multiples. SGHT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.3x EV/Revenue (-19.1% FCF margin), whereas ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.3x EV/Revenue (-18.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SGHT (-50.1% ROE) versus ECOR (-478.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SGHT carries 78.7% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.09β · 48% Vol realized risk). By comparison, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 155% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.